MX2010004971A - Metodos de identificacion de antagonistas seguros del receptor nmda. - Google Patents
Metodos de identificacion de antagonistas seguros del receptor nmda.Info
- Publication number
- MX2010004971A MX2010004971A MX2010004971A MX2010004971A MX2010004971A MX 2010004971 A MX2010004971 A MX 2010004971A MX 2010004971 A MX2010004971 A MX 2010004971A MX 2010004971 A MX2010004971 A MX 2010004971A MX 2010004971 A MX2010004971 A MX 2010004971A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- nmda receptor
- potency
- compound
- receptor antagonists
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan procesos para la identificación de un compuesto que es útil para tratar o evitar un trastorno que disminuye el pH en una región de tejido afectado, que comprende evaluar la diferencia en potencia, o disparo de potencia del compuesto a un pH fisiológico contra un pH inducido por el trastorno en una célula que expresa un receptor humano NMDA. La evaluación del disparo de potencia puede incluir medir un IC50 de un compuesto a un pH fisiológico y a un pH inducido por un trastorno (el "disparo de potencia") hasta un 95% de intervalo de confianza para que el disparo de potencia no cambie más de 15% con la adición de un nuevo experimento, en donde las mediciones se repiten al menos 5 veces. Los procesos se pueden usar para la selección de antagonistas de un receptor seguro NmDA para el tratamiento o prevención de un trastorno humano que disminuya el pH en una región de tejido afectado. Tales trastornos incluyen, pero no se limitan a, dolor neuropático, isquemia, mal de Parkinson, epilepsia y lesiones traumáticas del cerebro.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98592407P | 2007-11-06 | 2007-11-06 | |
| US98592207P | 2007-11-06 | 2007-11-06 | |
| PCT/US2008/082660 WO2009061935A2 (en) | 2007-11-06 | 2008-11-06 | Methods of identifying safe nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010004971A true MX2010004971A (es) | 2010-07-28 |
Family
ID=40626437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010004971A MX2010004971A (es) | 2007-11-06 | 2008-11-06 | Metodos de identificacion de antagonistas seguros del receptor nmda. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2212694A4 (es) |
| JP (1) | JP2011503013A (es) |
| KR (1) | KR20100100858A (es) |
| CN (1) | CN101918832A (es) |
| AU (1) | AU2008323877A1 (es) |
| BR (1) | BRPI0820406A2 (es) |
| CA (1) | CA2704475A1 (es) |
| EA (1) | EA201070571A1 (es) |
| IL (1) | IL205432A0 (es) |
| MX (1) | MX2010004971A (es) |
| WO (1) | WO2009061935A2 (es) |
| ZA (1) | ZA201003724B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014159960A (ja) * | 2011-06-08 | 2014-09-04 | Astellas Pharma Inc | 慢性疼痛モデル動物における自発痛行動自動測定法 |
| SG10202007661XA (en) * | 2015-05-22 | 2020-09-29 | Vistagen Therapeutics Inc | Therapeutic uses of l-4-chlorokynurenine |
| US10583171B2 (en) | 2015-11-30 | 2020-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | NMDAR antagonists for the treatment of diseases associated with angiogenesis |
| CN111960514A (zh) * | 2020-08-28 | 2020-11-20 | 浙江浙能技术研究院有限公司 | 一种用于脱硫废水浓缩的电渗析智能控制系统及方法 |
| EP4395783A4 (en) | 2021-09-02 | 2025-11-26 | Univ Emory | SELECTIVE ANTAGONISTS OF THE GLUN2B SUBUNITY OF N-METHYLD-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACID PH |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072542A2 (en) * | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
| KR20030063765A (ko) * | 2002-01-24 | 2003-07-31 | 엘지전자 주식회사 | 광픽업용 대물렌즈 |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| CN1894279A (zh) * | 2003-12-16 | 2007-01-10 | 安万特药物公司 | 分泌性神经凋亡抑制蛋白 |
| WO2006023957A1 (en) * | 2004-08-23 | 2006-03-02 | Emory University | Improved selection of-ph dependent compounds for in vivo therapy |
-
2008
- 2008-11-06 MX MX2010004971A patent/MX2010004971A/es active IP Right Grant
- 2008-11-06 BR BRPI0820406-3A patent/BRPI0820406A2/pt not_active IP Right Cessation
- 2008-11-06 EA EA201070571A patent/EA201070571A1/ru unknown
- 2008-11-06 CA CA2704475A patent/CA2704475A1/en not_active Abandoned
- 2008-11-06 EP EP08847388A patent/EP2212694A4/en not_active Withdrawn
- 2008-11-06 AU AU2008323877A patent/AU2008323877A1/en not_active Abandoned
- 2008-11-06 KR KR1020107012419A patent/KR20100100858A/ko not_active Withdrawn
- 2008-11-06 WO PCT/US2008/082660 patent/WO2009061935A2/en not_active Ceased
- 2008-11-06 CN CN2008801240927A patent/CN101918832A/zh active Pending
- 2008-11-06 JP JP2010532343A patent/JP2011503013A/ja active Pending
-
2010
- 2010-04-29 IL IL205432A patent/IL205432A0/en unknown
- 2010-05-25 ZA ZA2010/03724A patent/ZA201003724B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2704475A1 (en) | 2009-05-14 |
| EA201070571A1 (ru) | 2010-12-30 |
| JP2011503013A (ja) | 2011-01-27 |
| KR20100100858A (ko) | 2010-09-15 |
| EP2212694A4 (en) | 2011-10-12 |
| EP2212694A2 (en) | 2010-08-04 |
| BRPI0820406A2 (pt) | 2015-05-19 |
| WO2009061935A3 (en) | 2009-08-20 |
| CN101918832A (zh) | 2010-12-15 |
| AU2008323877A1 (en) | 2009-05-14 |
| WO2009061935A2 (en) | 2009-05-14 |
| IL205432A0 (en) | 2010-12-30 |
| ZA201003724B (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gruenewald et al. | Monitoring the nociception–anti-nociception balance | |
| Chalaye et al. | Comparing pain modulation and autonomic responses in fibromyalgia and irritable bowel syndrome patients | |
| MX2010004971A (es) | Metodos de identificacion de antagonistas seguros del receptor nmda. | |
| MX2007010064A (es) | Sistema y metodo de prediccion de respuesta al tratamiento neurologico, usando el electroencefalograma. | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| MXPA05006123A (es) | Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. | |
| WO2009097526A3 (en) | Brain-related chronic pain disorder treatment method and apparatus | |
| MY148461A (en) | Heteroaryl amide analogues as p2x7 antagonists | |
| Zhang et al. | EEG patterns from acute to chronic stroke phases in focal cerebral ischemic rats: correlations with functional recovery | |
| DE602008005735D1 (de) | Verfahren und vorrichtung für eeg-elektrode mit schnellem andruck | |
| IL193765A0 (en) | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | |
| WO2008071438A3 (en) | Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor | |
| PH12012500938A1 (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| Bjørk et al. | The occipital alpha rhythm related to the “migraine cycle” and headache burden: a blinded, controlled longitudinal study | |
| TW200510373A (en) | Substituted quinolin-4-ylamine analogues | |
| Domínguez et al. | A transient postnatal quiescent period precedes emergence of mature cortical dynamics | |
| WO2008024433A3 (en) | Haloalkyl-substituted pyrimidinone derivatives | |
| EA200900330A1 (ru) | Аналоги 2-феноксипиримидинона | |
| MY145822A (en) | Substituted biaryl piperazinyl-pyridine analogues | |
| Rowley et al. | Differential effects of phenytoin and sodium valproate on seizure-induced changes in γ-aminobutyric acid and glutamate release in vivo | |
| Zhang et al. | Effects of clobenpropit on pentylenetetrazole-kindled seizures in rats | |
| Giulioni et al. | Focal epilepsies associated with glioneuronal tumors | |
| Chan et al. | Short versus long-acting local anaesthetic in open carpal tunnel release: which provides better preemptive analgesia in the first 24 hours? | |
| WO2006042289A3 (en) | Substituted biaryl quinolin-4-ylamine analogues | |
| EP2716285A3 (en) | New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |